Global Chronic Kidney Disease Drugs Market 2019-2025: Increasing CKD Incidence, Ageing Population, Promising Repayments & Reimbursement Plans - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 22, 2019--
The “Chronic Kidney Disease Drugs Market - Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.
The report predicts that the Global Chronic Kidney Disease Drugs Market will grow at a CAGR of 4.1% during the forecast period
The market has witnessed flat growth in the past few years and is sustaining only due to the steady rise in the incidence of renal disorders leading to chronic kidney disease, increasing incidences of cardiovascular and metabolism-related disorders, and growing geriatric population globally.
The growing market trend continues and is one of the increasingly accepted markets in many countries worldwide. Chronic kidney disease drugs manufacturers are focusing on obtaining funds and collaborating with universities to enlarge their R&D capabilities. A majority of the revenue is generated from the leading players in the market with dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and AstraZeneca.
According to the author’s analysis, North America accounted for the largest share of the global chronic kidney disease drugs market in 2018. The US dominates the market owing to the presence of a majority of the chronic kidney disease drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the large kidney disease patient population and increasing awareness about the disease.
The antihypertensives segment occupied the largest share in 2018. Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2 randomized clinical trial on KBP-5074 for patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
In 2018, hospitals accounted for the maximum share, followed by speciality clinics, due to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition.
North America is dominant in the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market comes from the US due to the availability of good reimbursement policies.
Various initiatives are taken by government establishments and market players to increase awareness among individuals. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. Many countries are focusing on national programs to create disease awareness, prevention, and treatment options; for example, country-level national dialysis program, kidney disease education portals, the launch of kidney-related disorder treatment funding initiatives, etc. Exhaustive pipeline for chronic kidney disease drugs is promising and is much required for future market growth.
For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase-III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is currently in phase III to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD).
Key Competitive Facts
Key Topics Covered:
1 Industry Outlook
2 Report Outline
3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Active pharmaceutical ingredients (APIs)
3.4.2 Over-the-counter drugs (OTC)
3.4.3 Human Insulin
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
126.96.36.199 High incidence of chronic kidney disease (CKD)
188.8.131.52 Rise in incidence of cardiovascular disorders and diabetes
184.108.40.206 Increase in global geriatric population
220.127.116.11 Competition from biosimilars
18.104.22.168 Complex drug development process
22.214.171.124 Promising Drug Pipeline Chronic Kidney Disease
126.96.36.199 Market expansion opportunities in emerging nations
188.8.131.52 Novel therapeutic approaches such as cell therapy
5.1.4 DRO - Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.2 Erythropoiesis-stimulating agents (ESAs)
6.3 Diuretics Drugs
7 End Users: Market Size and Analysis
7.3 Specialty Clinic
8 Regions: Market Size and Analysis
9 Competitive Landscape
10 Vendors Profile
10.1 AbbVie Inc.
10.1.2 Geographic Presence
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Amgen Inc.
10.3 GlaxoSmithKline plc
10.4 F. Hoffmann-La Roche Ltd.
10.5 Astra Zeneca PLC
11 Companies to Watch for
11.1 Pfizer Inc.
11.3 Teva Pharmaceutical Industries Ltd.
11.4 Johnson & Johnson
11.5 Keryx Biopharmaceuticals Inc
11.6 FibroGen Inc.
For more information about this report visit https://www.researchandmarkets.com/r/pahun1
View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005307/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/22/2019 04:23 AM/DISC: 05/22/2019 04:23 AM